Mitsubishi Tanabe Pharma issues its news to provide stakeholders with the latest information related to the Company. Information on products or drug candidates may be included, but is intended to provide for the media, etc. It is not intended for promotion, advertising or medical advice. Information is current as of the date of issue of the individual news. Please be advised that information may be outdated after that point.
Information RADICAVA ORS now available in U.S. for treatment of ALS
June 16, 2022
Mitsubishi Tanabe Pharma America Inc., a sales subsidiary of Mitsubishi Tanabe Pharma Corporation announced RADICAVA ORS is now available in the United States.
Press Release[PDF:114KB](June 15, 2022)